Plant genomics' ascent
News Feb 03, 2010
Emily Waltz, Nature Biotechnology 28, 10 (2010)
supporting plant genome research in the US have reached an all-time
high. Over 2009, the National Science Foundation (NSF) doled out nearly
$102 million, the largest sum since the annual
grant program began in 1998.
The funding aims to increase understanding of plant gene function and the interaction of plant genomes and the environment. “This funding lets you tackle bigger problems,” says David Salt, a former grant recipient and plant biologist at Purdue University. “It lets you devise more integrated and collaborative projects.” The NSF chose 32 projects focused on “economically important crop plants” ranging from West African cultivated rice to poplar trees, according to the foundation.
The largest award, worth more than $10.4 million over four years, went to a proposal to help complete the international effort to sequence the tomato genome. James Giovannoni at Cornell University's Boyce Thompson Institute for Plant Research in Ithaca, New York, leads the project. The NSF also chose for the first time a switchgrass research project. With a grant worth more than $4.5 million, Thomas Juenger and his team at the University of Texas at Austin will explore over the next four years how switchgrass responds to drought and other stresses caused by climate change, to expand the knowledge needed to develop switchgrass as a biofuel crop.
Back in 2009, researchers identified a herd of Awassi sheep suffering from "day blindness". As that term implies, these sheep were blind during the day (in bright light) but could see at night, in low-light conditions. After identifying the genetic basis of this blindness, researchers have now successfully used gene therapy to restore their daytime vision.READ MORE
The National Institutes of Health announced the launch of a new initiative to help speed the development of cures for sickle cell disease. The Cure Sickle Cell Initiative will take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.